Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Angiotensin Receptor Blockers (ARBs) Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The market for angiotensin receptor blockers (arbs) has experienced continuous expansion in recent years. It is anticipated to increase from $8.78 billion in 2025 to $9.18 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.6%. The expansion observed historically can be ascribed to several factors, including the rising occurrence of hypertension, increased public awareness regarding cardiovascular ailments, the expansion of hospital infrastructures, the development of new arb molecules, and intensified research efforts in kidney disease treatments.
The angiotensin receptor blockers (ARBs) market size is projected to demonstrate consistent expansion over the upcoming years, with expectations to reach $11.02 billion in 2030, driven by a compound annual growth rate (CAGR) of 4.7%. This growth during the forecast period is primarily attributed to an aging population, the increasing demand for personalized medicine, ongoing technological advancements in drug delivery systems, a rise in healthcare expenditure, and the continued expansion of specialty clinics. Prominent trends for the forecast period include personalized hypertension management, an increase in treatments for chronic kidney disease, the broadening scope of cardiovascular disease therapies, a higher adoption rate of oral ARB formulations, and a noticeable rise in prescriptions originating from hospitals and specialty clinics.
Get A Free Sample Report With In-Depth Market Insights:
Angiotensin Receptor Blockers (ARBs) Market Growth Backed By Core Demand Fundamentals
The escalating occurrence of cardiovascular diseases is projected to drive the expansion of the angiotensin receptor blockers market moving forward. Cardiovascular disease (CVD) encompasses any ailment affecting the heart or blood vessels, commonly linked with the accumulation of fatty deposits within arteries (atherosclerosis) and a heightened probability of blood clots. Angiotensin receptor blockers work by reducing blood pressure and enhancing the heart’s pumping capability by facilitating the relaxation of veins and arteries, thereby mitigating the risk of cardiovascular disease. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease climbed to 233.3 per 100,000 in 2024, an increase of 4.0% from 224.4 per 100,000 in 2023. Thus, the increasing incidence of cardiovascular diseases is propelling the growth of the angiotensin receptor blockers market.
Angiotensin Receptor Blockers (ARBs) Market Segment Landscape And Growth Outlook
The angiotensin receptor blockers (arbs) market covered in this report is segmented –
1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan
2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications
3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers
Angiotensin Receptor Blockers (ARBs) Market Growth Trends Reshaping The Competitive Landscape
Leading companies in the angiotensin receptor blocker market are developing advanced products, such as angiotensin receptor neprilysin inhibitors, to enhance treatment options and improve patient outcomes for cardiovascular conditions. Angiotensin receptor neprilysin inhibitors (ARNIs) represent a class of medications employed in treating heart failure. For instance, in January 2023, Glenmark Pharmaceuticals, an India-based pharmaceutical company, introduced sacubitril + valsartan tablets, specifically targeting heart failure, particularly heart failure with reduced ejection fraction (HFrEF). This combination is classified under ARNI (angiotensin receptor neprilysin inhibitors). Sacubitril functions by boosting the natriuretic peptide (NP) system, which helps alleviate fluid overload and encourages blood vessel dilation, while valsartan works by obstructing the renin-angiotensin system (RAS) to reduce blood pressure and lessen the heart’s strain. Together, they effectively mitigate heart failure symptoms, decrease the risk of cardiovascular mortality, and lower the chances of hospitalization due to heart failure. These are sold under the brand name Sacu V.
Angiotensin Receptor Blockers (ARBs) Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the angiotensin receptor blockers (arbs) market are Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, AbbVie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma, Thermo Fisher Scientific.
View The Full Angiotensin Receptor Blockers (ARBs) Market Report:
Angiotensin Receptor Blockers (ARBs) Market Regional Analysis And Top Geography
North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2025. The regions covered in the angiotensin receptor blockers (arbs) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model